메뉴 건너뛰기




Volumn 589, Issue 2, 2015, Pages 231-239

Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma

Author keywords

Cancer; Chemotherapeutic agents; Drug resistance; Osteopontin overexpression

Indexed keywords

FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OSTEOPONTIN; VITRONECTIN RECEPTOR;

EID: 84920740895     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.12.004     Document Type: Article
Times cited : (14)

References (48)
  • 3
    • 0038387494 scopus 로고    scopus 로고
    • 5-Fluorouracil: Mechanisms of action and clinical strategies
    • D.B. Longley, D.P. Harkin, and P.G. Johnston 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 5 2003 330 338
    • (2003) Nat. Rev. Cancer , vol.3 , Issue.5 , pp. 330-338
    • Longley, D.B.1    Harkin, D.P.2    Johnston, P.G.3
  • 4
    • 33847244929 scopus 로고    scopus 로고
    • Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
    • D.B. Longley, W.L. Allen, and P.G. Johnston Drug resistance, predictive markers and pharmacogenomics in colorectal cancer Biochim. Biophys. Acta 1766 2 2006 184 196
    • (2006) Biochim. Biophys. Acta , vol.1766 , Issue.2 , pp. 184-196
    • Longley, D.B.1    Allen, W.L.2    Johnston, P.G.3
  • 5
    • 50949094432 scopus 로고    scopus 로고
    • 5-Fluorouracil: Mechanisms of resistance and reversal strategies
    • N. Zhang, Y. Yin, S.J. Xu, and W.S. Chen 5-Fluorouracil: mechanisms of resistance and reversal strategies Molecules 13 8 2008 1551 1569
    • (2008) Molecules , vol.13 , Issue.8 , pp. 1551-1569
    • Zhang, N.1    Yin, Y.2    Xu, S.J.3    Chen, W.S.4
  • 7
    • 0002445885 scopus 로고
    • Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas
    • Y. Shimosato, S. Oboshi, and K. Baba Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas Jpn. J. Clin. Oncol. 1 1 1971 19 35
    • (1971) Jpn. J. Clin. Oncol. , vol.1 , Issue.1 , pp. 19-35
    • Shimosato, Y.1    Oboshi, S.2    Baba, K.3
  • 9
    • 7044264360 scopus 로고    scopus 로고
    • Role of osteopontin in adhesion, migration, cell survival and bone remodeling
    • T. Standal, M. Borset, and A. Sundan Role of osteopontin in adhesion, migration, cell survival and bone remodeling Exp. Oncol. 26 3 2004 179 184
    • (2004) Exp. Oncol. , vol.26 , Issue.3 , pp. 179-184
    • Standal, T.1    Borset, M.2    Sundan, A.3
  • 10
    • 72949119124 scopus 로고    scopus 로고
    • Integrins in cancer: Biological implications and therapeutic opportunities
    • J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 1 2009 9 22
    • (2009) Nat. Rev. Cancer , vol.10 , Issue.1 , pp. 9-22
    • Desgrosellier, J.S.1    Cheresh, D.A.2
  • 11
    • 0029816589 scopus 로고    scopus 로고
    • 5-Fluorouracil in colorectal cancer, a never ending story
    • R. Herrmann 5-Fluorouracil in colorectal cancer, a never ending story Ann. Oncol. 7 6 1996 551 552
    • (1996) Ann. Oncol. , vol.7 , Issue.6 , pp. 551-552
    • Herrmann, R.1
  • 12
    • 1642576129 scopus 로고    scopus 로고
    • Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays
    • H.C. Kang, I.J. Kim, J.H. Park, Y. Shin, J.L. Ku, M.S. Jung, B.C. Yoo, H.K. Kim, and J.G. Park Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays Clin. Cancer Res. 10 1 Pt. 1 2004 272 284
    • (2004) Clin. Cancer Res. , vol.10 , Issue.1 , pp. 272-284
    • Kang, H.C.1    Kim, I.J.2    Park, J.H.3    Shin, Y.4    Ku, J.L.5    Jung, M.S.6    Yoo, B.C.7    Kim, H.K.8    Park, J.G.9
  • 13
    • 3042631054 scopus 로고    scopus 로고
    • Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line
    • B.C. Yoo, E. Jeon, S.H. Hong, Y.K. Shin, H.J. Chang, and J.G. Park Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line Clin. Cancer Res. 10 12 Pt 1 2004 4176 4184
    • (2004) Clin. Cancer Res. , vol.10 , Issue.12 , pp. 4176-4184
    • Yoo, B.C.1    Jeon, E.2    Hong, S.H.3    Shin, Y.K.4    Chang, H.J.5    Park, J.G.6
  • 14
    • 8544224306 scopus 로고    scopus 로고
    • Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells
    • W. Wang, J. Cassidy, V. O'Brien, K.M. Ryan, and E. Collie-Duguid Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells Cancer Res. 64 22 2004 8167 8176
    • (2004) Cancer Res. , vol.64 , Issue.22 , pp. 8167-8176
    • Wang, W.1    Cassidy, J.2    O'Brien, V.3    Ryan, K.M.4    Collie-Duguid, E.5
  • 15
    • 77955376177 scopus 로고    scopus 로고
    • Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression
    • S.L. Petersen, M. Peyton, J.D. Minna, and X. Wang Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression Proc. Natl. Acad. Sci. USA 107 26 2010 11936 11941
    • (2010) Proc. Natl. Acad. Sci. USA , vol.107 , Issue.26 , pp. 11936-11941
    • Petersen, S.L.1    Peyton, M.2    Minna, J.D.3    Wang, X.4
  • 16
    • 0030064334 scopus 로고    scopus 로고
    • Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
    • G.F. Weber, S. Ashkar, M.J. Glimcher, and H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 5248 1996 509 512
    • (1996) Science , vol.271 , Issue.5248 , pp. 509-512
    • Weber, G.F.1    Ashkar, S.2    Glimcher, M.J.3    Cantor, H.4
  • 17
    • 6344258588 scopus 로고    scopus 로고
    • The role of osteopontin in tumor metastasis
    • P.Y. Wai, and P.C. Kuo The role of osteopontin in tumor metastasis J. Surg. Res. 121 2 2004 228 241
    • (2004) J. Surg. Res. , vol.121 , Issue.2 , pp. 228-241
    • Wai, P.Y.1    Kuo, P.C.2
  • 18
    • 57049166456 scopus 로고    scopus 로고
    • Osteopontin: Role in immune regulation and stress responses
    • K.X. Wang, and D.T. Denhardt Osteopontin: role in immune regulation and stress responses Cytokine Growth Factor Rev. 19 5-6 2008 333 345
    • (2008) Cytokine Growth Factor Rev. , vol.19 , Issue.56 , pp. 333-345
    • Wang, K.X.1    Denhardt, D.T.2
  • 19
    • 0027131418 scopus 로고
    • Osteopontin: A protein with diverse functions
    • D.T. Denhardt, and X. Guo Osteopontin: a protein with diverse functions FASEB J. 7 15 1993 1475 1482
    • (1993) FASEB J. , vol.7 , Issue.15 , pp. 1475-1482
    • Denhardt, D.T.1    Guo, X.2
  • 20
    • 0032432558 scopus 로고    scopus 로고
    • Osteopontin expression and function: Role in bone remodeling
    • D.T. Denhardt, and M. Noda Osteopontin expression and function: role in bone remodeling J. Cell. Biochem. 30-31 1998 92 102
    • (1998) J. Cell. Biochem. , vol.30-31 , pp. 92-102
    • Denhardt, D.T.1    Noda, M.2
  • 21
    • 35548995858 scopus 로고    scopus 로고
    • Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production
    • K.X. Wang, Y. Shi, and D.T. Denhardt Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production Proc. Natl. Acad. Sci. USA 104 37 2007 14777 14782
    • (2007) Proc. Natl. Acad. Sci. USA , vol.104 , Issue.37 , pp. 14777-14782
    • Wang, K.X.1    Shi, Y.2    Denhardt, D.T.3
  • 25
    • 2942511574 scopus 로고    scopus 로고
    • Role of osteopontin in tumor progression
    • S.R. Rittling, and A.F. Chambers Role of osteopontin in tumor progression Br. J. Cancer 90 10 2004 1877 1881
    • (2004) Br. J. Cancer , vol.90 , Issue.10 , pp. 1877-1881
    • Rittling, S.R.1    Chambers, A.F.2
  • 26
    • 77956442992 scopus 로고    scopus 로고
    • Osteopontin is a marker for cancer aggressiveness and patient survival
    • G.F. Weber, G.S. Lett, and N.C. Haubein Osteopontin is a marker for cancer aggressiveness and patient survival Br. J. Cancer 103 6 2010 861 869
    • (2010) Br. J. Cancer , vol.103 , Issue.6 , pp. 861-869
    • Weber, G.F.1    Lett, G.S.2    Haubein, N.C.3
  • 27
    • 78651376714 scopus 로고    scopus 로고
    • Categorical meta-analysis of osteopontin as a clinical cancer marker
    • G.F. Weber, G.S. Lett, and N.C. Haubein Categorical meta-analysis of osteopontin as a clinical cancer marker Oncol. Rep. 25 2 2011 433 441
    • (2011) Oncol. Rep. , vol.25 , Issue.2 , pp. 433-441
    • Weber, G.F.1    Lett, G.S.2    Haubein, N.C.3
  • 32
    • 84898835302 scopus 로고    scopus 로고
    • Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma
    • M. Mardani, A. Andisheh-Tadbir, B. Khademi, M.J. Fattahi, S. Shafiee, and M. Asad-Zadeh Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma Tumor Biol. 35 4 2014 3827 3829
    • (2014) Tumor Biol. , vol.35 , Issue.4 , pp. 3827-3829
    • Mardani, M.1    Andisheh-Tadbir, A.2    Khademi, B.3    Fattahi, M.J.4    Shafiee, S.5    Asad-Zadeh, M.6
  • 33
    • 26444467146 scopus 로고    scopus 로고
    • Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial
    • Danish Head And Neck Cancer Study Group
    • J. Overgaard, J.G. Eriksen, M. Nordsmark, J. Alsner, M.R. Horsman, and Danish Head and Neck Cancer Study Group Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Lancet Oncol. 6 10 2005 757 764
    • (2005) Lancet Oncol. , vol.6 , Issue.10 , pp. 757-764
    • Overgaard, J.1    Eriksen, J.G.2    Nordsmark, M.3    Alsner, J.4    Horsman, M.R.5
  • 37
    • 26944478634 scopus 로고    scopus 로고
    • Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer
    • Y. Zhu, D.T. Denhardt, H. Cao, P.D. Sutphin, A.C. Koong, A.J. Giaccia, and Q.T. Le Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer Oncogene 24 43 2005 6555 6563
    • (2005) Oncogene , vol.24 , Issue.43 , pp. 6555-6563
    • Zhu, Y.1    Denhardt, D.T.2    Cao, H.3    Sutphin, P.D.4    Koong, A.C.5    Giaccia, A.J.6    Le, Q.T.7
  • 38
    • 33751162608 scopus 로고    scopus 로고
    • Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels
    • M. Bache, R. Reddemann, H.M. Said, H.J. Holzhausen, H. Taubert, A. Becker, T. Kuhnt, G. Hänsgen, J. Dunst, and D. Vordermark Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels Int. J. Radiat. Oncol. Biol. Phys. 66 5 2006 1481 1487
    • (2006) Int. J. Radiat. Oncol. Biol. Phys. , vol.66 , Issue.5 , pp. 1481-1487
    • Bache, M.1    Reddemann, R.2    Said, H.M.3    Holzhausen, H.J.4    Taubert, H.5    Becker, A.6    Kuhnt, T.7    Hänsgen, G.8    Dunst, J.9    Vordermark, D.10
  • 39
    • 84876544010 scopus 로고    scopus 로고
    • Upregulation of drug transporter expression by osteopontin in prostate cancer cells
    • I.S. Hsieh, W.H. Huang, H.C. Liou, W.J. Chuang, R.S. Yang, and W.M. Fu Upregulation of drug transporter expression by osteopontin in prostate cancer cells Mol. Pharmacol. 83 5 2013 968 977
    • (2013) Mol. Pharmacol. , vol.83 , Issue.5 , pp. 968-977
    • Hsieh, I.S.1    Huang, W.H.2    Liou, H.C.3    Chuang, W.J.4    Yang, R.S.5    Fu, W.M.6
  • 41
    • 58749094152 scopus 로고    scopus 로고
    • Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells
    • G. Song, Y. Ming, Y. Mao, S. Bao, and G. Ouyang Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells Exp. Biol. Med. (Maywood) 233 12 2008 1537 1545
    • (2008) Exp. Biol. Med. (Maywood) , vol.233 , Issue.12 , pp. 1537-1545
    • Song, G.1    Ming, Y.2    Mao, Y.3    Bao, S.4    Ouyang, G.5
  • 42
    • 0033929141 scopus 로고    scopus 로고
    • Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met)
    • A.B. Tuck, B.E. Elliott, C. Hota, E. Tremblay, and A.F. Chambers Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) J. Cell. Biochem. 78 3 2000 465 475
    • (2000) J. Cell. Biochem. , vol.78 , Issue.3 , pp. 465-475
    • Tuck, A.B.1    Elliott, B.E.2    Hota, C.3    Tremblay, E.4    Chambers, A.F.5
  • 44
    • 38149098569 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against avb3 integrin receptor, in patients with advanced solid tumors
    • C. Delbaldo, E. Raymond, K. Vera, L. Hammershaimb, K. Kaucic, S. Lozahic, M. Marty, and S. Faivre Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against avb3 integrin receptor, in patients with advanced solid tumors Invest. New Drugs 26 1 2008 35 43
    • (2008) Invest. New Drugs , vol.26 , Issue.1 , pp. 35-43
    • Delbaldo, C.1    Raymond, E.2    Vera, K.3    Hammershaimb, L.4    Kaucic, K.5    Lozahic, S.6    Marty, M.7    Faivre, S.8
  • 45
    • 77949394260 scopus 로고    scopus 로고
    • A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin avb3 ± dacarbazine in patients with stage IV metastatic melanoma
    • P. Hersey, J. Sosman, S. O'Day, J. Richards, A. Bedikian, R. Gonzalez, W. Sharfman, R. Weber, T. Logan, M. Buzoianu, L. Hammershaimb, J.M. Kirkwood, and Etaracizumab Melanoma Study Group A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin avb3 ± dacarbazine in patients with stage IV metastatic melanoma Cancer 116 6 2010 1526 1534
    • (2010) Cancer , vol.116 , Issue.6 , pp. 1526-1534
    • Hersey, P.1    Sosman, J.2    O'Day, S.3    Richards, J.4    Bedikian, A.5    Gonzalez, R.6    Sharfman, W.7    Weber, R.8    Logan, T.9    Buzoianu, M.10    Hammershaimb, L.11    Kirkwood, J.M.12
  • 48
    • 79957671402 scopus 로고    scopus 로고
    • Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: Findings of the phase i part
    • J.B. Vermorken, J. Guigay, R. Mesia, J.M. Trigo, U. Keilholz, A. Kerber, U. Bethe, M. Picard, and T.H. Brummendorf Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part Br. J. Cancer 104 11 2011 1691 1696
    • (2011) Br. J. Cancer , vol.104 , Issue.11 , pp. 1691-1696
    • Vermorken, J.B.1    Guigay, J.2    Mesia, R.3    Trigo, J.M.4    Keilholz, U.5    Kerber, A.6    Bethe, U.7    Picard, M.8    Brummendorf, T.H.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.